Skip to content

Menu

LexBlog, Inc. logo
NetworkSub-MenuBrowse by SubjectBrowse by PublisherJoin the NetworkGet StartedSubscribeSupport
Contact Us
Search
Close

Webinar | FDA’s Regulation of Stem Cells and Regenerative Medicine in Light of Regenerative Sciences

By Mike Druckman, Michael P. Levinson & Randy Prebula on March 21, 2014
Email this postTweet this postLike this postShare this post on LinkedIn

Hogan Lovells invites you to a 60-minute webinar on FDA’s Regulation of Stem Cells and Regenerative Medicine in Light of Regenerative Sciences. The webinar will take place Tuesday, April 1, 2014 at 1:00 p.m. ET and will cover the following topics:

  • Can stem cell therapies still be considered within the practice of medicine and outside the realm of FDA oversight?
  • The implications of Regenerative Sciences with respect to pre- and post-market oversight.
  • The effect of growing demand for stem cell treatments and the risks of medical tourism to countries with inadequate regulatory oversight.
  • Development models: practical pathways from research to profitability.

The webinar will feature moderator Michael Druckman and speakers Michael Levinson, M.D., J.D. Randy Prebula, and the founder and executive director of the Genetics Policy Institute Bernard Siegel, who is also the founder and co-chair of the World Stem Cell Summit.

Update: Listen to the webinar here.

  • Posted in:
    Health Care and Life Sciences
  • Blog:
    Focus on Regulation
  • Organization:
    Hogan Lovells
  • Article: View Original Source

Call us at 1-800-913-0988 or email sales@lexblog.com.

Facebook LinkedIn Twitter RSS
  • About LexBlog
  • The Field We Built
  • Our Beliefs
  • Our Team
  • Contact LexBlog
  • Disclaimer
  • Editorial Policy
  • Terms of Service
  • Get Started
  • Publishing Solutions
  • Compass
  • Submit a Request
  • Support Center
  • System Status
Copyright © 2026, LexBlog, Inc. All Rights Reserved.
Law blog design & platform by LexBlog LexBlog Logo